Extended Data Figure 1 : Epidemiological and pre-clinical data of the anti-cancer effects of DSF.

From: Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4

Extended Data Figure 1

a, Summary of hazard ratios (HR) and 95% confidence intervals (CI) for cancer-specific mortality among Danish patients with cancer, comparing continuing and previous users of DSF for selected types of cancer (for statistical analysis and definitions of DSF exposure categories, see Methods). b, Photographs of subcutaneously growing human MDA-MB-231 tumours extracted from mice at day 32.c, Time-course diagram of mouse weight. n = 8 animals per group. d, Model of CuET formation during metabolic processing of orally administered DSF in the human body. e, Examples of mass-spectrometry spectra of CuET expressed as peaks of 4 MRM transitions in mouse serum after CuET spikes, compared to orally applied DSF (50 mg kg−1). Data are representative of two independent experiments. f, Pharmacokinetic analysis of CuET levels in mouse serum after orally applied DSF (50 mg kg−1). n = 2 animals per time point. g, Effect of DTC and CuET on MDA-MB-231 cells analysed by colony formation assay. n = 3 independent experiments. h, Time-course diagram of weight in CuET- and vehicle-treated mice. n = 10 animals per group. i, Extended time-course diagram of weight in CuET- and vehicle-treated mice. n = 10 animals per group. Data are mean ± s.d. (c, h, i) or linked means (g).